Androgen receptor signaling contributes to targeted therapy resistance in melanoma: Inhibiting androgen receptor improved treatment response in preclinical study
Androgen receptor (AR) signaling affects response to BRAF/MEK inhibitor therapy in both males and females with melanoma, researchers from The University of Texas MD Anderson Cancer Center showed in a study published today in Nature. The findings provide a new target to combat therapeutic resistance and one possible answer to why men face a poorer prognosis than women when diagnosed with melanoma.
The AR is a type of nuclear receptor that’s activated by the male sex hormone testosterone. Females have lower levels of androgens, including testosterone. This research confirms the impact of biological sex on response to BRAF/MEK targeted therapy and shows for the first time that these inhibitors increase AR signaling, leading to therapeutic resistance and poor response to treatment. In preclinical models of melanoma, blocking the AR improved response to BRAF/MEK targeted therapy in both males and females.
“This study, coupled with other recent publications looking at the impact of AR signaling on response to other types of cancer therapies, such as immune checkpoint blockade, has enormous implications for the field,” said senior corresponding author Jennifer Wargo, M.D., professor of Genomic Medicine and Surgical Oncology. “We know males and females get cancer at different rates and have different mortality. Our research raises the possibility that the AR and testosterone may be at play and offers a new target to improve response to treatment in both sexes.”
Biological sex matters for targeted therapy response in melanoma
The study began with an observation from a neoadjuvant clinical trial for BRAF/MEK inhibitors in stage III melanoma (NCT02231775) where female patients had a higher rate of major pathologic response (MPR, defined as <10% viable tumor at time of surgery) rates and recurrence-free survival (RFS) rates than male patients.
To validate these findings, the group studied additional patients with locally advanced metastatic melanoma, including 51 patients treated with neoadjuvant BRAF/MEK inhibitors (30 females and 21 males). The MPR rate was 66% for females and 14% for males, and the two-year RFS rate was 64% for females and 32% for males.
Source: Read Full Article